Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Institutional Owners: 11 total, 11 long only, 0 short only, 0 long/short - change of -80.56%
Lost 80% of the few remaining "tutes" from the last quarter.
Likely at death's door and a step away from bankruptcy. That million they borrowed last month ain't gonna take them far. Not a good sign when what amounts to pawning the Company’s Eligible Equipment. That puts shareholders at the end of the line.
hey Mista Redsputter - only moron here is you sport
my buys were for my buys - not yours genius - lolzzz
IBIO great trading stock son
buy buy buy while the shorts accumulate
oh by the by - hows dat TOMDaFk you been Boiler Room Pumpin doing…?
oh they went insolvent - bahwahbawhabaha ….!
Redsputter - reputation permanently shot…
MOO shizzel head
30 ‘Tutes’ have filed this year
30 ‘Tutes’ have sold out 100%
Where is that moron JP stock analyst who told everybody to Buy Buy Buy?
Should get investigated for fraud
https://fintel.io/so/us/ibio
So far IBIO 10 for 10 on ‘tutes’ dumping 100% of their holdings this year according to the most recent 13s. No wonder why that stock analyst moron went into hiding. Should get his ass sued off for telling people to BUY BUY BUY. I hear he’s penniless now after putting his life savings into 1 stock.
13's coming in
Shabby who got charged with Naked Shorting got themselves 200K shares cover shares?
SEC Charges Investment Adviser and Principal in Abusive Naked Short Selling Scheme
https://www.sec.gov/news/press-release/2023-107
But look at all that pink!
100% of the 13's coming in from the 'tutes' so far this year total sold 100%. Must have no stomach for a soon to be 4th RS.
Wonder if the expert stock analyst is still touting this stock from $2000+ pre 3 RSs to a buckaroo. Prolly hung up his shingle and retired from pumping stocks.
https://fintel.io/so/us/ibio
What happened to the iBIO stock 'touter' JPetroInc?
The one that was pumping on multiple BIO stocks as a fake stock analyst?
Isn't that illegal to post on social media and message boards telling people to buy without any disclosures or financial training and certifications?
If you do that simple math...
Wasn't that from $2000+ a share to a buck the fake stock analyst was 'touting' iBIO apparently trying to con others it seems?
Is it time for class action to sue these low life stock pumpers for every penny they have now that iBIO pawned their last remaining tangible assets?
Example of the pumping these con artist do on BIO stocks
For every time he said congratulations, maybe he pushed his nose further up the CEO azz? I hear he has a brown nose.
http://content.stockpr.com/amarantus/media/782786d417b8894297ed7f45f31a9e42.pdf
IBIO will surprise...
With their 4th RS to stay above a $1
Won't help them stay listed though with a $2M market cap.
That stock analyst that was telling people to buy IBIO should go to jail.
almost like “we” knew it was coming
Something to think about. Using 'simple math'...
If IBIO didn't do the RSs, it would be a 0.0006 stock right now.
Whoever that idiot that was telling people to 'Buy Buy Buy' and average down, got clobbered.
The first split for IBIO took place on June 11, 2018. This was a 1 for 10 reverse split.
The second split took place on October 10, 2022. This was a 1 for 25 reverse split.
The third split took place on November 29, 2023. This was 1 for 20 reverse split.
Holy Dilution Batman!
After the RS, the OS was 1,405,036 shares and lookie how many IBIO trying to unload with the offering. Warrants exercisable immediately too.
Using 'Simple Math' with rounded numbers
Authorized Shares: 275,000,000
Stock Price $0.20
20 to 1 RS = $4.00
Dilution Potential: $1B+
Oops they did it again...
They didn't do a proportional split on the AS.
Just like last RS IBIO will have plenty of shares once again to dilute.
What a beating IBIO took today.
The first split for IBIO took place on June 11, 2018. This was a 1 for 10 reverse split.
The second split took place on October 10, 2022. This was a 1 for 25 reverse split.
The third will take place on November 29, 2023. This will be a 1 for 20 reverse split.
Notice how they are coming quicker?
But wait, there is more...
Market Cap: $5.62 million
Guess what's next?
20-to-1 reverse split in two days.
Let's see. If you bought a boat load of stock at $5, you needed the stock to get to $125 after the last RS to break even. After this one using simple math, you would need $2,500. Should there be a class action again the company and the IBIO stock pumper who pretends to be a stock analyst giving out financial advice without a license?
iBio Announces Reverse Stock Split - November 27 2023
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) effective at 12:01 a.m. ET on November 29, 2023 (the “Effective Date”). The Common Stock is expected to begin trading on a split-adjusted basis when the market opens on November 29, 2023, with the new CUSIP number 451033708.
The reverse stock split was authorized by iBio’s stockholders at the Company’s 2023 Annual Meeting, held earlier today, with a ratio ranging from 1-for-5 to 1-for-20 (the “Range”), with the ration within such Range to be determined at the discretion of the Company’s Board of Directors. As a result of the reverse stock split, every 20 shares of the Company's Common Stock issued and outstanding will be automatically combined into one share of common stock, with no change in the $0.0001 par value per share. Holders of fractional shares will be entitled to receive a cash payment equal to the number of shares of the Common Stock held by such stockholder before the reverse stock split that would otherwise have been exchanged for such fractional share interest multiplied by the average closing sales price of the Common Stock as reported on the NYSE American for the ten days preceding the Effective Date. As a result of the reverse split, the number of shares of the Company’s outstanding Common Stock will be reduced from 28,100,733 shares to 1,405,036 shares.
The exercise prices of all outstanding stock options, warrants, and equity incentive plans will be adjusted in accordance with their respective terms. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of the Company's shares with the exception of those holders of fractional shares.
The Company’s transfer agent, Continental Stock Transfer & Trust Company, which is also acting as the exchange agent for the reverse split, will send instructions to stockholders of record who hold stock certificates regarding the exchange of their old certificates for new certificates, should they wish to do so. Stockholders who hold their shares in brokerage accounts or “street name” are not required to take any action to effect the exchange of their shares.
https://ih.advfn.com/stock-market/AMEX/ibio-IBIO/stock-news/92661398/ibio-announces-reverse-stock-split
What happened to the other moderator? The one who invested here at $125 and was continually recommending BUY! BUY! BUY! ???
I can understand how one's heart just isn't in it anymore, after losing that much MONI. Probably had crow instead of turkey over Thanksgiving.
Printing: $0.2526 - 52 week low for IBIO.
Isn't that an all time low for IBIO?
I did try to warn you.
Maybe they will need to do a bigger RS.
If the sp drops to $0.15, that would only be $3 with the max 1-for-20 RS.
Maybe they would go with a 1-for-40?
"to approve an amendment to the Company’s Certificate of Incorporation, in substantially the form attached to the accompanying proxy statement as Appendix A, at the discretion of the Board of Directors of the Company, to effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.001 per share (“Common Stock”), including stock held by the Company as treasury shares, at a ratio of 1-for-5 to 1-for-20 (the “Range”), with the ratio within such Range (the “Reverse Stock Split Ratio”) to be determined at the discretion of the Board and included in a public announcement, subject to the authority of the Board of Directors to abandon such amendment;"
That was a nice trick they did so IBIO could continue to dilute to the tune over 25x the OS. I would bet the upcoming RS will be at the top of the range to 1:20 so when they dilute, it will give them more time before the share price slips from $6 back to $0.03 again.
IBIO had zero revenue from continued operations and only $4.3M of cash left in of June. How much are they burning per month? Is it $1M I didn't look.
Using simple math if that is the case they are OOC (Out of Cash), with no other revenue. Yike! Now they need to go to shady LPC and deal with Dickie. Watch the shorting begin after the RS by you know who.
Revenue
"During the Fiscal year ended June 30, 2023, the Company reported no revenue from continuing operations and generated
$391,000 of its revenue reported in discontinued operations from four customers. During the Fiscal year ended June 30,
2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a
revenue contract and generated $499,000 of revenue reported in discontinued operations from eight customers. "
Reverse Stock Split
"On October 7, 2022, we effected a reverse stock split at a ratio of one-for-twenty five (1:25) shares of our common stock.
As a result of the reverse stock split, every twenty five (25) shares of the Company's common stock either issued and
outstanding or held by us in our treasury immediately prior to the effective time was, automatically and without any action
on the part of the respective holders thereof, combined and converted into one (1) share of our common stock. The reverse
split also applied to common stock issuable upon the exercise of our outstanding stock options. The reverse stock split did
not affect the par value of our common stock or the shares of our common stock that we are authorized to issue under our
Certificate of Incorporation, as amended. No fractional shares were issued in connection with the reverse stock split.
Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead
were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. All share and per share
amounts of common stock presented in this Annual Report have been retroactively adjusted to reflect the one-for-twenty
five reverse stock split."
https://ir.ibioinc.com/sec-filings##document-18796-0001420720-23-000062-2
I wonder if the authorized shares will remain unchanged like during the last reverse split. Wouldn't that be something?
BUY BUY BUY!!!
Buy all you can. When you mention to friends you bought at below 0.30, be sure to ignore the RS and tell the the current after-RS price to impress them and solidify your position as an investment GURU. LMAO
You called this RS many months ago. Spot on.
Where's the fake analyst when you need some commentary on this fantastic investment?
And there you go...
Yet another RS. For those that still can remember things, IBIO did a 1 for 25 a year ago on October 10th.
"...to approve an amendment to the Company’s Certificate of Incorporation, in substantially the form attached to the accompanying proxy statement as Appendix A, at the discretion of the Board of Directors of the Company, to effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.001 per share (“Common Stock”), including stock held by the Company as treasury shares, at a ratio of 1-for-5 to 1-for-20 (the “Range”), with the ratio within such Range (the “Reverse Stock Split Ratio”) to be determined at the discretion of the Board and included in a public announcement, subject to the authority of the Board of Directors to abandon such amendment;"
https://ih.advfn.com/stock-market/AMEX/ibio-IBIO/stock-news/92285111/form-pre-14a-other-preliminary-proxy-statements
Up to Seven Amendments now...
A clear sign IBIO out of cash and needs to tap into Reserve Funds Deposit Account as they don't have enough MONey to make it to the end of the year.
New Friday evening filing out. Nice try to bury it.
They got the form right...
Form POS AM - Post-Effective amendments for registration statement
https://ih.advfn.com/stock-market/AMEX/ibio-IBIO/stock-news/92163208/form-pos-am-post-effective-amendments-for-regist
I forgot they had a shelf out there to dump $200M from 'time to time'. No wonder the stock tanked among other issues.
Remember, IBIO didn't RS the AS equally like they did the share price. IBIO has 275,000,000 AS. Pleny o room for dilution x10
But wait. There is more
The spruce goose isn't being sold for the $30M-$40M the fake stock analyst was saying...
"The Purchase and Sale Agreement provides that the Property will be sold to Majestic Realty for a purchase price of $17,250,000, or the Purchase Price."
All this was in the 10-K if anyone read it anyway.
Right, which is one reason I don't look at charts. They are always split adjusted. It's absolute garbage how they show it.
iBio Announces Filing of 2023 Annual Report on SEC Form 10-K - SEPTEMBER 27, 2023
BRYAN, Texas and SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the filing of its annual report on Form 10-K with the United States Securities and Exchange Commission ("SEC") for the fiscal year ended June 30, 2023
Revenues for the fiscal year ended June 30, 2023 were $nil, compared to $1.9 million in fiscal 2022. Total operating expenses, not including the loss from discontinued operations, were $29.3 million in fiscal 2023, a 7% decrease from $31.6 million in fiscal 2022. iBio's consolidated net loss for the fiscal year ended June 30, 2023 was $65.0 million, an increased loss of $14.6 million compared to 2022, due primarily to increased loss from discontinued operations. iBio held cash and cash equivalents of $4.3 million, and restricted cash of $3.3 million, as of June 30, 2023.
Pursuant to the disclosure requirements of the NYSE American Company Guidelines Sections 401(h) and 610(b), the Company advises that its audited financial statements for the fiscal year ended June 30, 2023, included in its annual report on Form 10-K filed today with the SEC, contained an audit opinion from its independent registered public accounting firm related to the Company’s ability to continue as a going concern. This announcement is made pursuant to NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph.
Subsequent to fiscal 2023 year end, iBio announced an amendment to its credit agreement (the “Credit Agreement”) with Woodforest National Bank (the “Agreement”), extending the Agreement’s maturity date from November 1, 2023 to the earlier of December 31, 2023 or the acceleration of maturity of the term loan in accordance with the Credit Agreement. The extension of the maturity date was intended to afford the Company sufficient time to close the pending sale of its cGMP biologics manufacturing facility (the “CDMO Facility”), which is anticipated to occur before the end of calendar 2023. There can be no assurance that the closing conditions for the sale of the CDMO Facility will be satisfied.
“Once the pending sale of the CDMO Facility closes, and the Woodforest loan is paid in full, for which there can be no assurance, it will complete the divestiture of iBio’s contract development and manufacturing business in Texas, and extend our cash runway to help support continued advancement of our AI drug discovery platform and immunotherapy pipeline out of our research and development center in California,” said Martin Brenner, DVM, Ph.D., iBio’s Chief Executive Officer and Chief Scientific Officer.
https://ir.ibioinc.com/news-events/press-releases/detail/211/ibio-announces-filing-of-2023-annual-report-on-sec-form-10-k
Charts go by those numbers. Just take a look. I see the stock over $125.
https://www.google.com/search?q=ibio+chart&rlz=1C1SQJL_enUS886US886&oq=ibio+chart&aqs=chrome..69i57j69i60l3.3639j0j4&sourceid=chrome&ie=UTF-8
You asked me who was recommending the stock at $125. I went back to pull the posts. I don't check the moron's posts. He's an idiot.
I have never seen anyone go by those numbers besides you, but to each their own.
If you have him on ignore, why do you check his messages? He can't talk to anybody here because nobody's here.
I have the fake stock analyst that is trying to con people on ignore. He's just s stock pumper after all and a bad one at that. You were asking about the $125 buys. You do realize if people say $5, it can mean different things pre or post split. Most people will factor in the splits when discussing share price or say post/presplit. The stock was at $5 multiple times due to reverse splits.
The fake stock analyst says he has a relationships with LPC too. IBIO's new piggybank. What what happens with this vulture funder.
Ok, but why not say $5, and why are you obsessed with the analyst? Just block him and be done with it.
If one bought at $5 like the 'stock analyst' before the 2nd reverse split, then that would have been $125 split adjusted.
Ouch, that was presplit so that would translate at $125.
It's never been $125.
That was thrown around Stocktwits forever during Covid because delusional people thought it would go that high.
It says 50 below the 15.
This is just a gutter stock that will die or one day we wake up and it's on the Moon. That's it, no in between... No hanging out at $5 for a while...
Who is it that recommended a buy at $125? How many years ago was that?
I think the minimums change a while ago during the Covid meltdown.
It's now $15M which they don't meet, now have no revenue and fired up the dilution machine with LPC which is a known vulture.
https://www.nyse.com/publicdocs/nyse/markets/nyse-american/MKT_Continued_Listing_Standards.pdf
'tutes' continue their dumping spree, even though the fake stock analyst recommended a buy at $125.
How does a garbage company like this manage to avoid being delisted for a Year? They have been well under the required $50 Million market cap for at least a Year.
Who was dumb enough to buy in the .40's premarket only to take a 25% haircut?
Was it the IBIO stock analyst?
iBio Announces Amendment to Credit Agreement with Woodforest - September 21 2023
https://ih.advfn.com/stock-market/AMEX/ibio-IBIO/stock-news/92100093/ibio-announces-amendment-to-credit-agreement-with
Maybe they get a few million out of the spruce goose in Texas. That ought to last them a few more months.
Take a look at IBIO's pipeline. They have nothing in trials. Absolutely NOTHING. They are years and 100's of millions away from getting through to Phase III. The stock analyst has said that before.
https://ibioinc.com/pipeline/
If they do…
it won’t be toxic death spiral dilutive financing…
that evicerates all shareholders like your love interest Gerald does to his TOMDF beleaguered shareholders
dumptin’s up w/Ibio Buchweat
nuff said …!
MOO shill n tout
Followers
|
442
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
27422
|
Created
|
11/13/08
|
Type
|
Free
|
Moderators |
iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field,
develops and offers pharmaceutical product applications using its iBio Technology platform.
The iBio Technology platform is a proprietary,
transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.
https://www.ibioinc.com/about/what-we-do
Because the cell line development phase is eliminated, FastPharming offers significant time savings compared to traditional expression platforms.
For instance, iBio produces milligram quantities of protein in as little as 6 weeks, gram quantities in 3 months, and greater than 10g of cGMP material in only 8 months.Additionally,
FastPharming processes are easily scalable, produce high quality product, are cost efficient, deliver improved safety, and facilitate superior glycosylation control.
IBio uses the FastPharming System to quickly produce biotherapeutic and vaccine candidates for unmet medical needs.
In the area of human disease, IBIO-100 targets fibrosis, a leading world-wide cause of organ failure.
IBIO-200 is a virus-like particle (VLP) vaccine designed as a rapid medical countermeasure solution to the COVID-19 outbreak.
The FastPharming platform produces a variety of recombinant products including:
The traditional approach to vaccines is to use live or killed viruses to generate immune responses.
Development, approval, and commercialization of these types of vaccines can take several years, a model that is clearly unfeasible during this pandemic.
New approaches use a reductionist approach by identifying key viral components that can be incorporated into a vaccine that elicits a strong immune response and is also safe and easy to manufacture.1
Such approaches include vaccines that rely on recombinant DNA or messenger RNA (mRNA).
San Diego-based Inovio Pharmaceuticals, the first company to advance a vaccine (INO-4700) against MERS-CoV into human testing,
is developing a DNA-based vaccine against COVID-19, while both Cambridge, Massachusetts-based Moderna and German biotech CureVac are developing mRNA-based vaccines.
There are concerns with many of these approaches, however, particularly DNA and mRNA vaccines.
Questions have been raised about their cold-chain requirements compared with traditional vaccine technology platforms.
These solutions provide great hope but carry significant risk.
At present, six COVID-19 or SARS-CoV-2 phase I clinical trials are listed in clinicaltrials.gov, although there are likely more in the works, as registration in the database is not mandatory until phase II.
Virus-like particles (VLPs) represent a promising alternative to soluble antigens, as their shape, size, repetitive antigen structure,
and geometry have been shown to trigger stronger immune response, both humoral and cellular.2 VLPs are artificial
constructs comprising multiple proteins organized to resemble a virus, but without including any viral genetic material, thereby rendering them non-infectious.
Because they have the components and conformation of the native virus, they can engender stronger and broader immune responses than the antigen itself.
In addition, VLPs can be produced as cost-effectively as other novel platform technologies being used for COVID-19 vaccine development
and do not present additional safety concerns compared with those associated with DNA- and mRNA-based solutions.
iBio has extensive capability in this area, having developed plant-based bioprocesses that generate VLPs with the
same structures as more traditional methods but via more efficient manufacturing routes. VLP platforms like iBio’s are advantageous because,
in addition to obtaining high yields of the individual VLP components, the components automatically self-assemble into a spherical VLP,
simplifying both the upstream and downstream purification processes involved in VLP manufacture.
The recent phase III clinical success of a VLP-based influenza vaccine produced in the N. benthamiana system
(NCT03739112, NCT03301051), both in terms of efficacy and safety, demonstrates the potential for plant-based VLP vaccine development.3
IBIO-200 is iBio’s lead COVID-19 vaccine candidate. iBio uses Woodchuck hepatitis virus and human hepatitis B virus core proteins
fused to COVID-19 receptor-binding motif (RBM), which self-assemble into empty nanoparticles.
The resulting VLPs form 40- to 50-nm diameter nanoparticles. The antigen is displayed in a repetitive structure and geometry,
and the particle is decorated with oligomannose molecules to more closely resemble the structure of naturally occurring viruses.
Oligomannose glycosylation is thought to lead to better cellular uptake of the VLPs by antigen-presenting cells via the mannose receptor.
As with other VLP-derived vaccines, IBIO-200 is designed to interact with immune cells differently than soluble antigens.
The production of IBIO-200 follows standard and highly optimized protocols. Plants are seeded,
germinated, and grown to 5 weeks of age in environmentally controlled grow rooms.
At 5 weeks, plants are vacuum infiltrated with Agrobacterium containing transient plant-specific expression vectors encoding COVID-19 antigen constructs.
After infiltration, the vector drives vaccine expression for 5–7 days; plant material is shredded, and total soluble protein extracted.
Preliminary scalable downstream processes have been designed, including concentration and buffer exchange of clarified extract capture and polishing chromatography.
For evaluation purposes, the first screenings measured expression and protein stability.
Selected candidates will then be injected into mice for an initial immunization study.
IgG response, cytokine profiling, and results of virus neutralization assays will dictate a second candidate screening.
Subsequently, selected candidates will enter toxicology studies in appropriate animal models to support an IND filling.
A lead candidate and a back-up will then be selected for further in vivo efficacy studies.
In parallel, iBio will develop a process that is scalable to cGMP manufacturing, prepare manufacturing documentation, and develop QC release assays.
The FastPharming manufacturing system delivers a tightly controlled particle size, providing considerable quality and scale-up advantages,
as uniform antigen display enables better dose definition and higher product yields.
All of this work will be based on technology proven successful for the clinical development of vaccine candidates in iBio’s U.S.-based,
large-scale production facility with all cGMP, QA, QC, scale-up, and regulatory resources;
the facility is self-contained and secure with highly reliable logistics.
iBio’s FastPharming facility was originally constructed in 2010 with funding from the Defense Advanced Research Projects Agency (DARPA),
part of the U.S. Department of Defense (DoD), which was exploring a range of technologies that could enable faster responses to outbreaks.
Plant-based expression technology won out, and the facility was one of three commercial sites comprising the “Blue Angel” initiative.
As part of the DARPA Blue Angel H1N1 Program, iBio’s facility was designed and built to manufacture kilogram quantities of
recombinant proteins within months versus the historically longer time frames needed for more traditional systems.
Its rapid launch to production has been designed specifically for medical countermeasure responses.
The iBio facility is among the largest biotherapeutic production facilities in the world for the production of recombinant protein in N. benthamiana,
with a current capacity to produce bulk clinical protein at the scale of approximately 500 million doses per year.
iBio technology has been used to produce a number of prophylactic vaccines, including soluble pathogen antigens formulated with adjuvants against anthrax,
H5N1 influenza, H1N1 influenza and hookworm, and a virus-like particle (VLP) formulated with an adjuvant against malaria.
Phase I clinical studies have been completed for all of these vaccine candidates.
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |